Cargando…

New indications and platforms for CAR‐T therapy in lymphomas beyond DLBCL

CD19‐directed chimeric antigen receptor T‐cell therapy (CAR‐T) represents a significant advancement for patients with relapsed/refractory large B‐cell lymphoma (LBCL). Long‐term follow‐up confirms durable remissions in nearly half of the patients, a population that was previously estimated to have a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Iqbal, Madiha, Savani, Bipin N, Hamadani, Mehdi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8725814/ https://www.ncbi.nlm.nih.gov/pubmed/34988550 http://dx.doi.org/10.1002/jha2.323

Ejemplares similares

CAR T-cell therapy for secondary CNS DLBCL
por: Ahmed, Gulrayz, et al.
Publicado: (2021)

Comorbidities in DLBCL: too "Severe4" CAR-T therapy?
por: Qualls, David, et al.
Publicado: (2023)

Overview of approved CAR‐T therapies, ongoing clinical trials, and its impact on clinical practice
por: Sengsayadeth, Salyka, et al.
Publicado: (2021)

Allogeneic transplant and CAR-T therapy after autologous transplant failure in DLBCL: a noncomparative cohort analysis
por: Hamadani, Mehdi, et al.
Publicado: (2022)

CAR T cell therapy in solid tumors: A review of current clinical trials
por: Patel, Urvi, et al.
Publicado: (2021)

Transformed Lymphoma Is Associated with a Favorable Response to CAR-T-Cell Treatment in DLBCL Patients
por: Nydegger, Anna, et al.
Publicado: (2021)

Glofitamab Treatment in Relapsed or Refractory DLBCL after CAR T-Cell Therapy
por: Rentsch, Vera, et al.
Publicado: (2022)

Salvage polatuzumab and allogeneic transplant rescue patients with B-cell lymphoma failing CAR T-cell therapy
por: Furqan, Fateeha, et al.
Publicado: (2022)

Custom CARs: Leveraging the Adaptability of Allogeneic CAR Therapies to Address Current Challenges in Relapsed/Refractory DLBCL
por: Jeyakumar, Nikeshan, et al.
Publicado: (2022)

Low toxicity and excellent outcomes in patients with DLBCL without residual lymphoma at the time of CD19 CAR T-cell therapy
por: Wudhikarn, Kitsada, et al.
Publicado: (2022)

DLBCL 1L—What to Expect beyond R-CHOP?
por: Stegemann, Maike, et al.
Publicado: (2022)

Therapy Strategy of CD47 in Diffuse Large B-Cell Lymphoma (DLBCL)
por: Zhang, Wenqi, et al.
Publicado: (2021)

Clinical and Product Features Associated with Outcome of DLBCL Patients to CD19-Targeted CAR T-Cell Therapy
por: Lamure, Sylvain, et al.
Publicado: (2021)

CAR-T Cell Therapy Shows Similar Efficacy and Toxicity in Patients With DLBCL Regardless of CNS Involvement
por: Shumilov, Evgenii, et al.
Publicado: (2023)

The Immunology of DLBCL
por: Takahara, Taishi, et al.
Publicado: (2023)

CAR T-cell therapy has comparable efficacy with autologous transplantation in older adults with DLBCL in partial response
por: Akhtar, Othman S., et al.
Publicado: (2023)

Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma
por: Zurko, Joanna, et al.
Publicado: (2022)

Lymphoma Microenvironment in DLBCL and PTCL-NOS: the key to uncovering heterogeneity and the potential for stratification
por: Miyawaki, Kohta, et al.
Publicado: (2022)

Genetic landscapes and curative effect of CAR T-cell immunotherapy in patients with relapsed or refractory DLBCL
por: Shi, Hui, et al.
Publicado: (2022)

The use of FDG-PET in diffuse large B cell lymphoma (DLBCL): predicting outcome following first line therapy
por: Coughlan, Monica, et al.
Publicado: (2014)

Retracted: Therapy Strategy of CD47 in Diffuse Large B-Cell Lymphoma (DLBCL)
por: Markers, Disease
Publicado: (2023)

CAR-T Cell Therapy for Classical Hodgkin Lymphoma
por: Katsin, Mikalai, et al.
Publicado: (2023)

Comparative analysis of CAR T-cell therapy access for DLBCL patients: associated challenges and solutions in the four largest EU countries
por: Canales Albendea, Miguel Á., et al.
Publicado: (2023)

PB2119: LONG-TERM SURVIVAL PROJECTIONS OF LONCASTUXIMAB TESIRINE-TREATED PATIENTS IN RELAPSED OR REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
por: Hamadani, M., et al.
Publicado: (2022)

Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond
por: Su, Christopher T., et al.
Publicado: (2021)

CAR T-Cell therapy for the management of mantle cell lymphoma
por: Huang, Zoufang, et al.
Publicado: (2023)

Beyond CAR T-Cell Therapy: Continued Monitoring and Management of Complications
por: Reiser, Victoria
Publicado: (2020)

CAR T-Cells for CNS Lymphoma: Driving into New Terrain?
por: Karschnia, Philipp, et al.
Publicado: (2021)

Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma: a review of clinical data
por: Furqan, Fateeha, et al.
Publicado: (2022)

Diffuse Large B-Cell Lymphoma (DLBCL): Early Patient Management and Emerging Treatment Options
por: Vodicka, Prokop, et al.
Publicado: (2022)

Oligoclonal T-cell expansion in a patient with bone marrow failure after CD19 CAR-T therapy for Richter-transformed DLBCL
por: Rejeski, Kai, et al.
Publicado: (2022)

Recent advances in CAR T-cell therapy for lymphoma in China
por: Che, Yuxuan, et al.
Publicado: (2023)

CAR-T Cell Therapy in Large B Cell Lymphoma
por: Testa, Ugo, et al.
Publicado: (2023)

Adoptive Immunotherapy beyond CAR T-Cells
por: Titov, Aleksei, et al.
Publicado: (2021)

Cellular Therapy Updates in B-Cell Lymphoma: The State of the CAR-T
por: Crees, Zachary D., et al.
Publicado: (2021)

CAR-T Cell Therapy in the Treatment of Pediatric Non-Hodgkin Lymphoma
por: Ostojska, Magdalena, et al.
Publicado: (2023)

Targeted Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Tafasitamab in Context
por: Abdulhaq, Haifaa, et al.
Publicado: (2023)

Timely Leukapheresis May Interfere with the “Fitness” of Lymphocytes Collected for CAR-T Treatment in High Risk DLBCL Patients
por: Farina, Mirko, et al.
Publicado: (2022)

CD19 CAR-T expressing PD-1/CD28 chimeric switch receptor as a salvage therapy for DLBCL patients treated with different CD19-directed CAR T-cell therapies
por: Liang, Yun, et al.
Publicado: (2021)

P1154: EFFICACY OF SUBCUTANEOUS EPCORITAMAB VS AXI-CEL IN R/R DLBCL CAR T-NAIVE AND CAR T-ELIGIBLE PATIENTS: AN INDIRECT COMPARISON
por: Thieblemont, Catherine, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_plestnktle1j4llqfqbqi53njo